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Abstract
Background: Methotrexate is a chemotherapeutic drug that is used in therapy of a wide variety of cancers. The 
efficiency of treatment with this drug is compromised by the appearance of resistance. Combination treatments of 
MTX with other drugs that could modulate the expression of genes involved in MTX resistance would be an adequate 
strategy to prevent the development of this resistance.
Methods: The differential expression pattern between sensitive and MTX-resistant cells was determined by whole 
human genome microarrays and analyzed with the GeneSpring GX software package. A global comparison of all the 
studied cell lines was performed in order to find out differentially expressed genes in the majority of the MTX-resistant 
cells. S100A4 mRNA and protein levels were determined by RT-Real-Time PCR and Western blot, respectively. 
Functional validations of S100A4 were performed either by transfection of an expression vector for S100A4 or a siRNA 
against S100A4. Transfection of an expression vector encoding for β-catenin was used to inquire for the possible 
transcriptional regulation of S100A4 through the Wnt pathway.
Results: S100A4 is overexpressed in five out of the seven MTX-resistant cell lines studied. Ectopic overexpression of this 
gene in HT29 sensitive cells augmented both the intracellular and extracellular S100A4 protein levels and caused 
desensitization toward MTX. siRNA against S100A4 decreased the levels of this protein and caused a 
chemosensitization in combined treatments with MTX. β-catenin overexpression experiments support a possible 
involvement of the Wnt signaling pathway in S100A4 transcriptional regulation in HT29 cells.
Conclusions: S100A4 is overexpressed in many MTX-resistant cells. S100A4 overexpression decreases the sensitivity of 
HT29 colon cancer human cells to MTX, whereas its knockdown causes chemosensitization toward MTX. Both 
approaches highlight a role for S100A4 in MTX resistance.
Background
Methotrexate (MTX) is a classical drug that is used for
the treatment of a wide variety of cancers, both alone and
in combination with other chemotherapeutic agents [1,2].
Drug resistance is usually observed upon treatment with
MTX, thus compromising its effectiveness. Combination
treatments of MTX with other drugs that could modulate
the expression of genes involved in MTX resistance
would be an adequate strategy to prevent the develop-
ment of resistance. W ith this premise, we searched for
genes differentially expressed in common among seven
MTX-resistant cell lines representative of five different
types of cancer. In that work we identified and validated
DHFR as the only gene overexpressed in common among
all the studied cell lines [3]. We also identified and vali-
dated other genes that, aside of DHFR, played an impor-
tant role in MTX resistance (AKR1C1, DKK1) [4] or that
indirectly contributed to the resistance phenotype
(MSH3, SSBP2, ZFYVE16) [5].
In the present report, we identified genes differentially
expressed in at least 4 out of the seven cell lines. Among
the genes that fulfilled this requisite, we found some
genes that we had previously studied as modulators of
MTX resistance, and S100A4, a gene overexpressed in
five out of the seven cell lines studied.
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S100A4 is a member of the S100 calcium binding pro-
tein family, which is composed of more than 20 members.
Their name was given because they are soluble in 100%
saturated ammonium sulfate [6]. As many of the S100
family members, S100A4 is a symmetric homodimer
characterized by the presence of two calcium binding
sites of the EF-hand type (helix-loop-helix) [7] that enable
S100 proteins to respond to calcium stimulus induced by
cell signaling.
S100A4 has been described to be involved in a wide
variety of intra- and extracellular processes, such as pro-
tein phosphorylation, dynamics of cytoskeleton compo-
nents or Ca2+ homeostasis, which are regulated through
interaction of S100A4 with its target proteins [8,9]. Over-
expression of S100A4 has been associated with tumor
malignancy [10] as well as to metastasis [11], angiogene-
sis [12] and chemoresitance [13].
In this work, we searched for genes differentially
expressed in common among cell lines resistant to MTX.
We identified S100A4 as a gene overexpressed in five out
of the seven MTX-resistant cell lines studied, which had
been previously associated with chemotherapy resis-
tance. Functional validations using either an expression
vector encoding for S100A4 or siRNA against its RNA
show a role for S100A4 in MTX resistance.
Methods
Cell Lines
Cell lines representative of five types of human cancer
were used: HT29 and Caco-2 of colon cancer, MCF-7 and
MDA-MB-468 of breast cancer, MIA PaCa-2 of pancre-
atic cancer, K562 of erythroblastic leukemia, and Saos-2
of osteosarcoma [3]. Resistant cells were obtained in the
laboratory upon incubation with stepwise concentrations
of MTX (Lederle) as previously described [4]. HT29,
Caco-2 and K562 resistant cells were able to grow in 10-
5M MTX, which corresponds to a 1000-fold increase in
resistance with respect to their respective sensitive cells;
MIA PaCa-2, Saos-2, MCF-7 and MDA-MB-468 were
resistant to 10-6M MTX, which represents an increase in
resistance of 100 times with respect to their sensitive
counterparts.
Cell Culture
Human cell lines were routinely grown in Ham's F12
medium supplemented with 7% fetal bovine serum (FBS,
both from Gibco) at 37°C in a 5% CO2 humidified atmo-
sphere. Resistant cells were routinely grown in selective
DHFR medium (-GHT medium, GIBCO) lacking glycine,
hypoxanthine and thymidine, the final products of DHFR
activity. This medium was supplemented with 7% dia-
lyzed fetal bovine serum (GIBCO).
Global microarray data analyses of cell lines resistant to 
MTX
A global comparison of all cell lines was performed using
GeneSpring GX v 7.3.1 (Agilent Technologies), using the
latest gene annotations available (March 2009), in order
to find differentially expressed genes in the majority of
the resistant cell lines. The triplicate samples for each
condition, sensitive and resistant, in each of the seven cell
lines (42 samples in total) were imported into one single
experiment. Normalization was applied in two steps: i)
"per Chip normalization" by which each measurement
was divided by the 50th percentile of all measurements in
its array; and ii) "per Gene normalization" by which the
samples of each cell line were normalized against the
median of the respective sensitive cells (control). The
expression of each gene was calculated as the ratio of the
value obtained for each condition relative to the control
condition after normalization of the data. Then, data
were filtered using the control strength, a control value
calculated using the Cross-Gene Error Model on repli-
cates [14] and based on average base/proportional value.
Measurements with higher control strength are relatively
more precise than measurements with lower control
strength. Genes that did not reach this value were dis-
carded. Additional filtering was performed to determine
the differentially expressed genes. We selected the genes
that displayed a p-value corrected by false discovery rate
(Benjamini and Hochberg FDR) of less than 0.05. A list
was generated with the genes that passed those filters in
at least four out of the seven resistant cell lines.
RT-Real-Time PCR
mRNA levels were determined by RT-Real-time PCR.
Total RNA was extracted from cells using Ultraspec™
RNA reagent (Biotecx) following the recommendations
of the manufacturer. Complementary DNA was synthe-
sized in a total volume of 20 μl by mixing 500 ng of total
RNA, 125 ng of random hexamers (Roche), in the pres-
ence of 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol,
20 units of RNasin (Promega), 0.5 mM dNTPs (Appli-
Chem), 200 units of M-MLV reverse transcriptase (Invit-
rogen) and 50 mM Tris-HCl buffer, pH 8.3. The reaction
mixture was incubated at 37°C for 60 min. The cDNA
product was used for subsequent Real-time PCR amplifi-
cation using an ABI Prism 7000 Sequence Detection Sys-
tem (Applied Biosystems) with 25 ng of the cDNA
mixture and the assays-on-demand from Applied Biosys-
tems Hs00243202_m1 for S100A4 and Hs00356991_m1
for APRT.
Gene copy number determination
Genomic DNA from either sensitive or resistant cells was
obtained with the Wizard™ Genomic DNA Purification
Kit (Promega) following the manufacturer's recommen-Mencía et al. BMC Cancer 2010, 10:250
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dations. We used 25 ng of DNA and the following prim-
ers for Real-Time PCR amplification: For S100A4: 5'-
CTTCTGG-GCTGCTTAT-3' and 5'-ACTGGGCT-
TCTGT-TTTCTATC-3'; and for APRT: 5'-CGGGAAC-
CCTCGTCTTTCGCC-3' and 5'-GCCTCGGG-GGCT-
CAATCTCAC-3'.
Preparation of total extracts for Western blotting
Total extracts from cells were used to assay S100A4 pro-
tein levels. Cells were scrapped in 700 μl of ice-cold PBS
and centrifuged for 10 min at 2,000 rpm on a microfuge.
The supernatant was discarded and cells were resu-
pended in 50 μl of RIPA buffer (50 mM Tris-HCl, 150
mM NaCl, 5 mM EDTA, 1% Igepal CA-630 (Sigma), 0.5
mM PMSF, Protease inhibitor cocktail from Sigma, 1 mM
NaF; pH 7.4). Cells were incubated in ice for 30 min with
vortexing every 10 minutes and then centrifuged at
15,000 × g at 4°C for 10 min. Five μl of the extract were
used to determine protein concentration by the Bradford
assay (Bio-Rad). The extracts were frozen in liquid N2 and
stored at -80°C. Different amounts of total extracts were
resolved on SDS 15%-polyacrylamide gels. After protein
transference using a semidry electroblotter, PVDF mem-
branes (Immobilon P, Millipore) were incubated with an
antibody against S100A4 (DAKO), and detection was
accomplished by secondary horseradish peroxidase-con-
jugated antibody and enhanced chemiluminescence, as
recommended by the manufacturer (Amersham). To nor-
malize the results, blots were re-probed with antibodies
against either Actin or GAPDH (Sigma).
Transfection of an expression vector encoding for S100A4
Cells were seeded into 6-well plates in 1 ml of HAM's F12
selective medium. Eighteen hours later, cells were trans-
fected with the expression plasmid for S100A4 (pCMV6-
XL5-S100A4, OriGene Technologies; abbreviated in the
manuscript as pCMV-S100A4), using either Lipo-
fectamine™2000 (Invitrogen) or Fugene (Roche) following
the manufacturer's specifications. The overexpression of
S100A4 was monitored by determining its mRNA levels
after 48 h and by determining its protein levels after 72 h
upon transfection, respectively. When assaying the sensi-
tivity to MTX caused by overexpression of S100A4, MTX
was added 48 h upon transfection and cell viability deter-
mined using the MTT assay 6 days after MTX addition.
An empty vector was transfected in parallel with pCMV-
S100A4 and was used as negative control.
ELISA assay
Cells were transfected with pCMV-S100A4 as described
above and cell culture media was collected 72 h after
transfection. Sandwich ELISA was performed in Max-
iSorb plates (NUNC), coated with a mouse anti-S100A4
antibody O/N at 4°C. Blocking was performed with 1%
BSA for 1 h at 37°C. Incubation with the samples was per-
formed for 2.5 h at 37°C, followed by incubation with a
rabbit anti-S100A4 antibody. Finally, incubation with a
secondary goat anti-rabbit horseradish peroxidase-conju-
gated antibody was performed for 1 h at 37°C. Reading of
absorbance upon TMB addition was performed in a Mul-
tiskan Ascent (Thermo) plate-reading spectrophotome-
ter at 630 nm. Background signal was determined in
parallel and was used to correct the absorbance values.
All analyses were performed at least in duplicate for each
sample in each experiment.
Transfection of siRNAs against S100A4 RNA
HT29 cells were plated in 1 ml of -GHT medium. Trans-
fection was performed eighteen hours later with a siRNA
designed against S100A4 RNA (siS100A4) or with a
siS100A4-4 MIS bearing 4 mismatches with respect to
siS100A4 (underlined in the sequence below).
siS100A4: 5'-CAGGGACAACGAGGTGGAC-3'
siS100A4-4 MIS: 5'-CACCCTCAACGAGGTGGAC-
3'
C e l l s  w e r e  l i p o f e c t e d  w i t h  t h e  s i R N A s  u s i n g  L i p o -
fectamine™2000 (Invitrogen) in accordance to the manu-
facturer's instructions. MTX (10-7M) was added 48 hours
after siRNA treatment and MTT assays were performed
as described previously [15] after 5 days from the treat-
ment with the siRNA. S100A4 knockdown was moni-
tored by determining its mRNA levels after 48 h and its
protein levels after 72 h upon siRNA transfection, respec-
tively.
The siRNAs were designed using the software iRNAi
v2.1. Among the possible alternatives, sequences rich in
A/T on the 3' of the target were chosen. Then, BLAST
resources in NCBI [16] were used to assess the degree of
specificity of the sequence recognition for these siRNAs.
We selected the siRNA that reported the target gene as
the only mRNA hit. To further assess siRNA specificity
for S100A4, we determined the mRNA levels of Enolase
2, Topoisomerase II, Clusterin and UGT1A7 upon incu-
bation with siS100A4 (off-target effects) by Real-Time
PCR using SYBR Green dye. See Additional file 1: Prim-
ers for off-target effects determination.
Transfection of an expression vector encoding for β-catenin
Cells were seeded into 6-well plates. Eighteen hours later,
transfection with the expression plasmid for β-catenin
(pcDNA3-β-catenin) kindly provided by Dr. Duñach,
U n i v e r s i t a t  A u t ò n o m a  d e  B a r c e l o n a ,  S p a i n )  w a s  p e r -
formed as described for pCMV-S100A4. Cells were col-
lected 48 h after transfection for RNA determination.
S100A4 mRNA levels were monitored by RT-Real-Time
PCR. The empty vector was transfected in parallel with
pcDNA3-β-catenin and was used as negative control.Mencía et al. BMC Cancer 2010, 10:250
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Statistical analyses
Data are presented as mean ± SE. Statistical analyses were
performed using the unpaired t test option in GraphPad
InStat version 3.1a for Macintosh. p-values of less than
0.05 were considered statistically significant.
Results
S100A4 is overexpressed but not amplified in human cells 
resistant to methotrexate
In previous studies, we used the HG U133 PLUS 2.0
microarrays from Affymetrix as a tool to analyze the dif-
ferential gene expression between sensitive and MTX-
resistant cells derived from different human cell lines rep-
resentative of colon cancer (HT29 and CaCo-2), breast
cancer (MCF-7 and MDA-MB-468), pancreatic cancer
(MIA PaCa-2), erythroblastic leukemia (K562) and osteo-
sarcoma (Saos-2) (GEO series accession number
[GSE16648], which also contains the current data). Now
we performed a global analysis of the seven cell lines to
find out genes differentially expressed in at least four out
of the seven cell lines. The list of these genes is provided
in Table 1. Among them, S100A4 was a gene differentially
expressed in five out of the seven cell lines and previously
reported to have a role in chemotherapy resistance [13].
We validated S100A4 overexpression in HT29, MCF-7,
MIA PaCa-2, K562 and Saos-2 resistant cell lines at the
levels of mRNA and protein, and determined that S100A4
upregulation in the resistant cells was not due to changes
in its gene copy number (Table 2).
Ectopic overexpression of S100A4 desensitizes HT29 cells 
toward MTX
HT29 MTX-resistant cells displayed the highest S100A4
expression values, considering both the mRNA and pro-
tein levels (Table 2). Thus, HT29 cells were selected for
further studies using an expression vector for S100A4
(pCMV-S100A4). Transfection with 250 ng of this vector
produced a 8-fold increase in the levels of S100A4 RNA
after 48 hours (Figure 1A). The intracellular levels of
S100A4 protein were also increased, reaching almost 5
fold when transfecting 1 μg of the expression plasmid
(Figure 1B). The overexpression of S100A4 was associ-
ated to a decrease in the sensitivity toward MTX (Figure
1C).
S100A4 is secreted by HT29 cells transfected with pCMV-
S100A4
Given that it had been described that S100A4 has extra-
cellular functions [12,17], we explored S100A4 protein
levels in the culture media of pCMV-S100A4 transfected
cells. The results from the ELISA assays showed
increased amounts of S100A4 protein in media from
transfected cells (Figure 1D), thus indicating that a frac-
tion of the protein produced upon vector transfection
was secreted outside the cells.
Knocking down S100A4 with siRNA chemosensitizes HT29 
toward MTX
We used iRNA technology to study the role of S100A4 in
MTX resistance. Treatment of sensitive HT29 cells with
increasing concentrations (10-100 nM) of the siRNA
against S100A4 (siS100A4) showed a progressive
decrease in its mRNA levels (Figure 2A), causing an 80%
reduction at 100 nM. This treatment also caused a vast
decrease in S100A4 protein levels (Figure 2B) and
increased the sensitivity of HT29 cells toward MTX by
about 50% (Figure 2C). To further assess siRNA specific-
ity for S100A4, we determined the mRNA levels of other
cellular genes upon incubation with siS100A4 (off-target
effects). These experiments did not show any significant
variation of the mRNA levels for Enolase 2, Topoi-
somerase II, Clusterin and UGT1A7 (Table 3)
Treatment with 100 nM siS100A4 was also performed
in HT29 MTX-resistant cells. This approach led to a
reduction of 75% in the levels of S100A4 RNA (Figure 3A)
but had no effect on cell viability (Figure 3B). A 4-mis-
match siRNA against S100A4 (siS100A4-4 MIS) was used
as negative control, and did not cause any significant
effects on S100A4 mRNA, protein levels or cell viability,
in neither of the two cell lines.
S100A4 is transcriptionally regulated by the Wnt pathway 
in HT29 cells
It had been previously described that S100A4 was a target
of the Wnt signaling pathway and a functional TCF bind-
ing site has been identified in its promoter sequence [18].
To investigate whether S100A4 expression was regulated
through this pathway in HT29 cells, we overexpressed β-
catenin in HT29 sensitive or resistant cells and quantified
S100A4 mRNA levels 48 h after transfection. A 2-fold
increase in S100A4 mRNA levels was observed upon
transfection of 1 μg of pcDNA3-β-catenin in HT29 sensi-
tive cells (Figure 4A) whereas no changes were obtained
when transfection was performed in HT29 resistant cells
(Figure 4B).
Discussion
The principal aim of this work was to find out genes dif-
ferentially expressed in cell lines resistant to MTX repre-
sentative of five different types of human cancer. In a
previous report [3], we determined and compared the
p a t t e r n s  o f  d i f f e r e n t i a l  g e n e  e x p r e s s i o n  a s s o c i a t e d  t o
MTX resistance in seven human cancer cell lines. In that
work, we established that the only differentially expressed
gene in common among all the cell lines studied was
DHFR. In the present work, we identified genes differen-
tially expressed in at least four out of the seven cell linesMencía et al. BMC Cancer 2010, 10:250
http://www.biomedcentral.com/1471-2407/10/250
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Table 1: Genes differentially expressed in at least four out of the seven MTX-resistant cell lines studied.
Genbank Gene Name Description Fold Change
HT29 Caco-2 MCF-7 MDA-
MB-468
MIA
PaCa-2
K562 SaOs-2
U05598 AKR1C2 aldo-keto reductase family 1, member C2 4.6 10.2 0.03 31.1 0.02 5.0 NS
AB018580 AKR1C3 aldo-keto reductase family 1, member C3 1.8 4.6 0.8 73.3 0.7 12.0 NS
NM_000691 ALDH3A1 aldehyde dehydrogenase 3 family, member A1 2.9 3.8 6.6 11.9 0.4 NS NS
AL136912 ATG10 ATG10 autophagy related 10 homolog 8.7 NS NS 1.5 2.1 10.1 2.0
U36190 CRIP2 cysteine-rich protein 2 2.7 1.3 1.9 NS 2.2 NS 0.3
NM_001321 CSRP2 cysteine and glycine-rich protein 2 2.0 0.3 2.7 NS 2.0 2.9 0.5
AU144855 CYP1B1 cytochrome P450, family 1, subfamily B, 
polypeptide 1
3.1 2.3 0.5 NS 4.2 NS 0.4
AI144299 DHFR dihydrofolate reductase 7.3 50.2 52.8 1.8 16.9 17.8 8.9
AA578546 DHFRL1 dihydrofolate reductase-like 1 7.0 10.8 5.5 NS 3.0 17.5 2.1
NM_012242 DKK1 dickkopf homolog 1 (Xenopus laevis) 4.3 2.5 2.1 NS 0.7 NS 19.1
AI745624 ELL2 elongation factor, RNA polymerase II, 2 NS 1.7 0.4 2.6 8.0 2.3 2.7
AF052094 EPAS1 endothelial PAS domain protein 1 2.8 NS 2.4 NS 6.4 0.4 0.1
AU144565 EPB41L4A erythrocyte membrane protein band 4.1 like 
4A
1.6 1.3 1.7 1.4 2.3 4.4 4.7
AW246673 FAM46A family with sequence similarity 46, member A NS 2.6 NS NS 3.9 2.5 1.5
NM_000142 FGFR3 fibroblast growth factor receptor 3 NS 4.6 3.1 0.4 1.5 0.4 3.4
NM_018071 FLJ10357 hypothetical protein FLJ10357 NS 3.8 NS NS 2.1 3.2 3.5
BE550452 HOMER1 homer homolog 1 (Drosophila) NS NS 27.9 NS 2.4 13.8 NS
AF243527 KLK5 kallikrein-related peptidase 5 2.3 NS 2.2 NS 3.5 NS 4.6
AK022625 LOC92270 V-type proton ATPase subunit S1-like protein 54.0 2.3 NS NS 3.4 25.0 NS
BC006471 MLLT11 myeloid/lymphoid or mixed-lineage leukemia 2.2 2.6 NS NS 1.8 0.08 1.7
NM_002439 MSH3 mutS homolog 3 (E. coli) 6.3 8.2 3,8 NS 13.2 35.9 1,5
NM_006117 PECI peroxisomal D3, D2-enoyl-CoA isomerase 7.5 2.6 1.9 NS NS NS 1.8Mencía et al. BMC Cancer 2010, 10:250
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studied. Among the genes that fulfilled this requisite, we
found some genes that we had previously validated and
reported to be directly associated with MTX resistance in
HT29 MTX-resistant cells (DHFR, AKR1C1 and DKK1)
or suggested to contribute to the phenotype in this cell
line (MSH3, SSBP2 and ZFYVE16) [3-5]. We also found
UGT1A6, a gene that seems to play a role in MTX resis-
tance in MCF-7 and in MDA-MB-468 cells (data not
shown). Among the other genes in the list, we selected,
for expression, genomic and functional validation,
S100A4, a gene overexpressed in five out of these seven
cell lines that was the only one previously reported to be
associated with chemoresistance [13]. This gene has also
been related with malignancy, metastasis, and tumor pro-
gression.
The human S100A4 is a member of the S100 family of
EF-hand Ca2+-binding proteins. The multigenic family of
S100 proteins is expressed in vertebrates exclusively and
has been described to play intracellular and extracellular
regulatory activities on protein phosphorylation, on the
dynamics of cytoskeleton components or on Ca2+ homeo-
stasis [8,9]. S100A4 in particular has been described to
have a function in cell cycle progression, in cell motility
and as a modulator of intercellular adhesion and of the
BF432873 PSMD11 proteasome 26 S subunit, non-ATPase, 11 NS 2.3 NS NS 1.3 3.5 1.4
NM_002923 RGS2 regulator of G-protein signaling 2, 24 kDa 1.6 8.2 3.6 NS 3.2 1.9 NS
AW043594 RPS23 ribosomal protein S23 12.9 NS NS NS 2.9 8.9 1.8
NM_005978 S100A2 S100 calcium binding protein A2 0.5 0.3 7.1 NS 4.0 NS 4.1
NM_002961 S100A4 S100 calcium binding protein A4 3.7 0.6 4.3 NS 2.4 1.5 2.5
AL565362 SLC2A13 solute carrier family 2, member 13 4.0 9.4 0.6 2.5 4.3 10.2 NS
BG150485 SLC6A6 solute carrier family 6, member 6 0.6 2.6 2.2 NS 2.4 1.5 1.5
NM_003069 SMARCA1 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
A, member 1
2.6 2.6 14.0 NS NS 3.4 1.7
NM_012446 SSBP2 single-stranded DNA binding protein 2 10.6 NS 0.5 NS 2.9 5.0 2.0
AW134979 STXBP6 syntaxin binding protein 6 (amisyn) NS 2.1 27.5 NS 3.0 14.5 0.5
NM_003248 THBS4 thrombospondin 4 NS 12.9 9.2 NS 15.7 4.9 0.6
BE873420 UGT1A6 UDP glucuronosyltransferase 1, polypeptide 
A6
NS 2.8 24.4 27.9 5.3 NS NS
AI922599 VIM vimentin 2.4 NS 3.6 NS NS 4.9 1.7
BE539792 ZCCHC9 zinc finger, CCHC domain containing 9 8.3 1.5 0.5 NS 6.7 7.9 NS
BU078629 ZFYVE16 zinc finger, FYVE domain containing 16 6.1 45.8 76.4 NS 16.5 23.1 3.2
A global comparison analysis was performed to find out differentially expressed genes in the majority of the MTX-resistant cells. The table 
includes the list of the genes differentially expressed in at least four out of the seven MTX-resistant cell lines that displayed a Benjamini-Hochberg 
false discovery rate-corrected p-value < 0.05. For each gene, the Genbank accession number, gene name, description and fold change in each 
resistant cell line with respect to its respective sensitive counterpart are shown. All values displayed are significant, unless otherwise stated (NS, 
non significant; p-value > 0.05)
Table 1: Genes differentially expressed in at least four out of the seven MTX-resistant cell lines studied. (Continued)Mencía et al. BMC Cancer 2010, 10:250
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invasive properties of cells [9,19] (see Sherbet et al. for a
review [20]). Several cancers, including colon cancer,
breast cancer and osteosarcoma, are known to produce
S100A4 [10], and particularly, HT29 cells have been
described to express a substantial amount of S100A4 [21].
Overexpression of S100A4 is more frequently found in
cancer cells than in normal colonic mucosa, as well as
more in liver metastasis than in primary tumors [21]. A
correlation between S100A4 expression levels and the
invasive potential of HT29 cells has been suggested [21].
S100A4 gene overexpression has been related to the
malignant potential of some tumors [10] and has been
closely associated with metastasis in several human can-
cers, including colorectal [21], breast [22,23], ovary [24],
thyroid [25], pancreatic [26], lung [27,28], esophageal
[29], prostate [30] and gastric cancer [31,32].
We tried to mimic the overexpression of S100A4 in the
resistant cells by transfecting HT29 sensitive cells with an
expression vector encoding for S100A4. We tested that
S100A4 mRNA and intracellular protein levels were sig-
nificantly increased after transfection. Importantly, we
could observe a reversion of the cytotoxicity caused by
MTX upon transfection with S100A4 expression vector.
It is worth mentioning that a moderate S100A4 overex-
pression has been described in a colon cancer cell line
resistant to doxorubicin [33]. S100P, another member of
the S100 family, has also been related to doxorubicin
resistance in colon cancer [33]. Moreover, S100A4
expression has been detected in patients that had
received adjuvant 5-fluorouracil, and has been proposed
to be a predictive factor of relapse in gastric cancer [34].
Likewise, S100P overexpression has been reported to
promote pancreatic cancer growth and increase cell sur-
vival after 5-fluorouracil exposure [35].
To investigate the role of intracellular S100A4 on MTX
resistance, we used iRNA technology. Transfection of a
siRNA against S100A4 in HT29 MTX-resistant cells
caused a reduction in gene RNA levels but did not alter
cell viability. The latter effect could be explained by the
overexpression by gene amplification of the dhfr locus in
this resistant cell line, which would mask the effects of
the siRNA used. However, when the same treatments
were performed in HT29 sensitive cells, carrying no dhfr
amplification, we could achieve a chemosensitization of
these cells toward MTX. These latter results are in agree-
ment with Mahon et al. [13] that showed that inhibition
of S100A4 expression resulted in an increased sensitivity
of pancreatic ductal adenocarcinoma cell lines to gemcit-
abine treatment and induced apoptosis. It has also been
described that S100A4 knockdown enhances the sensitiv-
Table 2: Validation of S100A4 overexpression and copy number determination in the different cell lines.
Cell Line Expression
Microarray
Signal Sensitive Signal Resistant Ratio RT-PCR Validation Copy- number Protein
HT29 1876 6862 3.7 6.2 ± 0.2 1.4 ± 0.1 22.5 ± 1.0
MCF-7 49 213 4.3 6.2 ± 0.3 1.5 ± 0.1 10.8 ± 2.2
MiaPaCa-2 3304 7925 2.4 4.7 ± 0.6 1.2 ± 0.1 24.4 ± 8.1
K562 147 249 1.5 3.6 ± 0.2 1.6 ± 0.1 4.0 ± 1.0
Saos-2 137 345 2.5 2.2 ± 0.1 2.16 ± 0.07 2 ± 0.4
CaCo-2 4515 2769 0.6 N/D N/D N/D
MDA-MB-
468
317 235 0.7 N/D N/D N/D
The table shows the S100A4 expression levels obtained in the microarray experiments for all the cell lines studied. The level of expression is 
presented as the mean of the signal value in sensitive and resistant cells, as well as the ratio between them (fold change). Gene overexpression 
was validated in five of the seven cell lines by RT-Real-Time PCR. S100A4 gene copy number was determined by Real-Time PCR. Protein levels were 
determined by Western blot using a specific antibody, and quantitation was performed upon densitometry of the images. Values represent the 
mean (in fold change relative to each respective sensitive cells) of three experiments ± SE; N/D, non-determined.Mencía et al. BMC Cancer 2010, 10:250
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Figure 1 Effects on S100A4 expression and MTX sensitivity upon pCMV-S100A4 transfection of HT29 cells. A) mRNA levels of S100A4 deter-
mined by RT-Real-Time PCR 48 h after treatment of HT29 cells (30,000) with 250 ng of the expression vector for S100A4 (pCMV-S100A4). B) A repre-
sentative image of the intracellular protein levels of S100A4 determined by Western Blotting 72 h after ectopic transfection with its expression vector 
is shown in the upper panel, and the quantification of the blots is shown in the lower panel. Purified S100A4 protein was used as a reference marker 
(Abnova; first lane). An additional panel showing endogenous S100A4 protein levels in HT29 sensitive (S) and resistant (R) cells is also provided. C) 
Effects of S100A4 overexpression on cell viability. HT29 cells (100,000) were treated with 1 μg of pCMV-S100A4 and 5 × 10-8M MTX was added 48 h 
later. Cell viability was assessed by the MTT assay six days after MTX treatment. D) Extracellular S100A4 protein levels quantified by ELISA 72 h after 
S100A4 overexpression upon pCMV-S100A4 transfection. The expression and viability results are expressed as percentages referred to the untreated 
cells. Values are the mean of three independent experiments ± SE. *p < 0.05, **p < 0.01, *** p < 0.001.
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ity of osteocarcinoma cells to undergo apoptosis [36] and
reverses the metastatic potential of osteosarcoma [37]
and lung carcinoma cells [28]. These reports together
with our results using either the expression vector or
siRNA technology, provide evidence that S100A4 acts as
a pro-survival factor that contributes, together with
DHFR, AKR1C1 and DKK1 (see above), to chemoresis-
tance in HT29 MTX-resistant cells. S100A4 could be
considered as biomarker of resistance in the sense that it
is overexpressed in the majority of the resistant cell lines
analyzed, and its determination is easy to perform. In
addition it could be considered as a drug target in the cat-
egory of resistance modulator using inhibitors of S100A4
as an adjuvant in MTX treatment.
In an attempt to determine the mechanism for the
overexpression of S100A4 in HT29 resistant cells, we
determined S100A4 copy number in both HT29 cell lines.
Although it has been previously described that the chro-
mosomal region where the gene is located (1q21) is
amplified in breast cancer [38,39] and in tumor tissue
from osteosarcoma patients [40], we did not observe copy
number changes for S100A4 in any of the cell lines stud-
ied. Other mechanisms have been proposed that attempt
to explain the mechanism for S100A4 overexpression: i)
by hypomethylation, since increased S100A4 expression
levels have been associated with decreased methylation
of the first intron of this gene in cell lines and carcinomas
of pancreatic origin [26] and of the second intron in colon
cancer cell lines [41]; and ii) through the Wnt signaling
pathway, given that it has been shown that S100A4 is a
target of this pathway in colon cancer and a functional
TCF binding site has been identified in its promoter
sequence [18]. In this sense, we had previously proposed
the activation of the Wnt/β-catenin pathway to be an
important step in MTX resistance in HT29 colon cancer
cells [5]. In this cell line, E-cadherin is lost at the chromo-
some level and underexpressed, thus allowing β-catenin
to play its function in gene transcription. In this direc-
tion, an inverse correlation has been established between
the expression levels of S100A4 and E-Cadherin [42] and
has been associated with poor differentiation of cancer
cells [31]. Moreover, transfection of an E-Cadherin
expression vector has been reported to cause a decrease
in S100A4 expression levels [43]. To further elucidate if
the Wnt signaling pathway could be responsible for the
increased expression levels of S100A4 in the resistant
cells, we overexpressed β-catenin and determined
Table 3: Assessment of siS100A4 specificity.
Gene S100A4 Enolase 2 Topoisomerase II Clusterin UGT1A7
Control 100 100 100 100 100
siRNA 
S100A4
18.6 ± 6 135.8 ± 21.6 127.5 ± 6.4 133.9 ± 14.4 159.5 ± 28.4
HT29 cells were transfected with 100 nM siS100A4. Forty-eight hours later, the mRNA levels of S100A4 and four unrelated genes were determined 
by RT-Real-Time PCR. Data represent the mean of three experiments ± SE.
Figure 2 Effects on S100A4 expression and MTX sensitivity upon 
siS100A4 transfection of HT29 cells. A) HT29 cells (30,000) were 
transfected with siS100A4 as described in Methods. Total RNA was ex-
tracted after 48 h and S100A4 mRNA levels were determined by RT-
Real-Time PCR. B) S100A4 protein levels were determined by Western 
Blotting 72 h after transfection, using specific antibodies against 
S100A4 and Actin to normalize the results. C) Chemosensitization as-
says toward methotrexate: cells were treated with siS100A4 for 48 h 
and then incubated with MTX. Cell viability was determined 3 days af-
ter MTX treatment. The expression and viability results are expressed as 
percentages referred to the untreated cells. Values are the mean of 
three independent experiments ± SE. A representative image of West-
ern Blots is presented. *p < 0.05, ** p < 0.01, *** p < 0.001.
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S100A4 mRNA levels. The resistant cells, which already
have the Wnt/β-catenin pathway highly activated, do not
respond to β-catenin overexpression. However, the
results obtained in HT29 sensitive cells showing a two-
fold increase in S100A4 mRNA expression upon β-
catenin transfection give support to a Wnt/β-catenin
pathway-mediated S100A4 transcription. Another target
of the Wnt signaling pathway that had been previously
related with MTX resistance is P-glycoprotein [44,45].
However, no changes in its expression levels were evi-
denced by our microarray results in HT29 cells (data not
shown).
Although many biological functions have been attrib-
uted to S100A4, the exact molecular mechanisms by
Figure 3 Effects on S100A4 expression and MTX sensitivity upon 
siS100A4 transfection of HT29 MTX-resistant cells. A) S100A4 
mRNA levels were determined by RT-Real-time PCR as described in 
Methods 48 h after siS100A4 treatment. B) Cells were treated with MTX 
after a 48 h-pre-incubation with siS100A4, and cell viability was deter-
mined 3 days later by the MTT assay. The levels of expression and the 
viability results are expressed as percentages referred to the untreated 
cells. Values are the mean of three independent experiments ± SE. *p 
< 0.05, ** p < 0.01.
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Figure 4 Effects of transfecting an expression vector encoding 
for β-Catenin on S100A4 mRNA levels. Transfection with β-Catenin 
expression vector (pcDNA3-β-Catenin) was performed in HT29 cells, 
both sensitive (Figure 4A) and resistant (Figure 4B) as described in 
Methods. S100A4 mRNA levels were determined by RT-Real-Time PCR 
48 h after transfection. All results are expressed as percentages referred 
to untreated cells. Values are the mean of three independent experi-
ments ± SE. * p < 0.05.
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which S100A4 exerts these functions have not been fully
elucidated [46]. Extracellular S100A4 has been related to
metastasis and angiogenesis [17,47,48] and has been
reported to activate NF-κB signaling. S100A4-mediated
activation of NF-κB has been proposed to repress the
expression of BNIP3, a pro-apoptotic member of the Bcl-
2 family, leading to decreased apoptosis [13] and
increased resistance to chemotherapy [49]. Our ELISA
experiments demonstrated that S100A4 ectopic overex-
pression in the sensitive cells leads to the secretion of a
fraction of the synthesized protein. Secretion of S100A4
by tumor cells has been previously demonstrated in vitro
[12]. One can hypothesize that secreted S100A4 would
contribute to resistance through BNIP3 regulation by the
NF-κB pathway in HT29 cells. However, our microarray
results show no changes in BNIP3 expression levels in
HT29 resistant cells (data not shown), thus suggesting
that this gene does not play a role in chemoresistance in
this cell line.
S100A4 has been reported to interact with p53, thus
interfering in p53 activation and DNA binding capacity
[50]. Mutations in p53 are frequently found in colorectal
cancer [51], and HT29 cells bear mutations in this gene.
These mutations reduce p53-dependent responses, thus
allowing the cells to continue to proliferate and therefore
give rise to drug resistance [52,53]. To further establish
MTX resistance, interaction between p53 and S100A4
would be necessary to reduce p53 remaining activity. The
significant 2-fold decrease in p53 expression levels in
HT29 resistant cells shown in our microarray results, in
accordance with others [54], would lead to increased pro-
liferation and reduced apoptosis, both of which would
contribute to MTX resistance.
In summary, our results show a role for S100A4 in
MTX resistance. Its overexpression in HT29 MTX-resis-
tant cells is not due to changes in gene copy-number but
to a transcriptional regulation, probably through the Wnt
pathway. Cellular knockdown of S100A4 leads to chemo-
sensitization toward MTX and ectopic gene overexpres-
sion desensitizes the cells toward this chemotherapeutic
agent.
Conclusions
S100A4 was identified and confirmed as a gene overex-
pressed in five out of the seven MTX-resistant cell lines
studied. S100A4 ectopic overexpression in HT29 cells
lead to a desensitization toward MTX. Conversely, trans-
fection experiments using interference RNA produced a
chemosensitization to MTX. The results obtained in this
report establish a relation between S100A4 and resistance
to MTX.
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